CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.

Lena AnderschJosefine RadkeAnika KlausSilke SchwiebertAnnika WinklerElisa SchumannLaura GrunewaldFelix ZirngiblCarina FlemmigMichael C JensenClaudia RossigAntonia JoussenAnton HenssenAngelika EggertJohannes H SchulteAnnette Künkele

Published in: BMC cancer (2019)

Both CD171 and GD2 are effective targets on human retinoblastoma cell lines, and CAR-T cell therapy is highly effective against retinoblastoma in vitro. Targeting of two different antigens by sequential CAR-T cell applications enhanced tumor cell killing and preempted tumor antigen loss in preclinical testing.

Keyphrases

cell therapy
induced apoptosis
stem cells
cell cycle arrest
mesenchymal stem cells
endothelial cells
dendritic cells